| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6280959 | NOVARTIS | Metal complexes |
Oct, 2018
(5 years ago) | |
| US7473686 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7452874 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(1 year, 5 months ago) | |
| US7547719 | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jul, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6280959 (Pediatric) | NOVARTIS | Metal complexes |
Apr, 2019
(4 years ago) | |
| US7332481 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
| US7790704 | NOVARTIS | Thrombopoietin mimetics |
May, 2021
(2 years ago) | |
|
US7790704 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7332481 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7452874 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7473686 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
Nov, 2021
(2 years ago) | |
|
US7160870 (Pediatric) | NOVARTIS | Thrombopoietin mimetics |
May, 2023
(11 months ago) | |
| US7795293 | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
May, 2023
(11 months ago) | |
|
US7795293 (Pediatric) | NOVARTIS | 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
Nov, 2023
(5 months ago) | |
|
US7547719 (Pediatric) | NOVARTIS | 3′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine) |
Jan, 2026
(1 year, 8 months from now) | |
Promacta Kit is owned by Novartis.
Promacta Kit contains Eltrombopag Olamine.
Promacta Kit has a total of 16 drug patents out of which 14 drug patents have expired.
Expired drug patents of Promacta Kit are:
- US6280959*PED
- US7332481
- US7790704
- US7790704*PED
- US7332481*PED
- US7452874*PED
- US7473686*PED
- US7160870*PED
- US7795293
- US7795293*PED
- US6280959
- US7473686
- US7452874
- US7160870
Promacta Kit was authorised for market use on 27 September, 2018.
Promacta Kit is available in for suspension;oral dosage forms.
Promacta Kit can be used as treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp), treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.
The generics of Promacta Kit are possible to be released after 13 January, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Nov 16, 2025 |
| New Dosing Schedule(D-149) | Jun 11, 2018 |
| New Indication(I-711) | Jun 11, 2018 |
| Orphan Drug Exclusivity(ODE) | Aug 26, 2021 |
| Pediatric Exclusivity(PED) | Feb 26, 2022 |
| Orphan Drug Exclusivity(ODE-74) | Aug 26, 2021 |
Drugs and Companies using
ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date:
27 September, 2018Treatment:
Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 ...Dosage:
How can I launch a generic of PROMACTA KIT before its drug patent expiration?
More Information on Dosage
PROMACTA KIT family patents
